This Danyelza market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.
Market growth during the historic period can be attributed to the increasing incidence of neuroblastoma, FDA approvals and regulatory support, broader clinical applications, higher research investments in immunotherapy, and growing healthcare expenditures.
Growth during the market's forecast period can be attributed to the increasing incidence of cancer, heightened awareness of targeted therapies, improved patient outcomes, growing demand for pediatric cancer treatments, and advancements in diagnostic tools. Key trends expected in the forecast period include progress in drug formulation, innovations in targeted therapy, greater outsourcing of clinical trials, integration of digital health solutions in clinical trials, and a stronger focus on pediatric research and innovation.
The rising prevalence of pediatric cancers is expected to drive the growth of the Danyelza market. Pediatric cancers include various types such as leukemia, brain tumors, neuroblastoma, and lymphomas that affect children and adolescents. This increase in pediatric cancer cases is linked to factors such as advancements in diagnostic techniques, environmental exposures, genetic factors, and the long-term effects of cancer treatments. Danyelza (naxitamab) is a targeted immunotherapy that plays a significant role in treating high-risk neuroblastoma, a type of cancer that can be difficult to manage. When used alongside other treatments, Danyelza has shown improvements in survival rates and has helped slow disease progression in children with this aggressive cancer. For example, in October 2024, the Cancer Council, an Australian non-profit organization, reported that in 2022, approximately 93 children aged 0-14 years died from cancer in Australia. In addition, there were 206 new cancer diagnoses in children under 15 and 263 in adolescents aged 15-24 in Victoria. By 2023, there were 6,197 males and 5,523 females alive who had been diagnosed with cancer during childhood or adolescence. The growing prevalence of pediatric cancers is thus driving the demand for Danyelza.
A significant trend in the Danyelza market is the development of targeted immunotherapy treatments that aim to improve options for treating neuroblastoma and other cancers. Targeted immunotherapy uses substances to directly target cancer cells, focusing on specific proteins or markers, such as GD2 in neuroblastoma, to help the immune system destroy the cancer cells. For example, in May 2023, Y-mAbs Therapeutics Inc., a US-based biotechnology company, received marketing authorization from Brazil's Agência Nacional de Vigilância Sanitaria for Danyelza (naxitamab-gqgk) 40 mg/10 mL injection, which is used to treat high-risk neuroblastoma. Danyelza is a recombinant humanized monoclonal antibody designed to target GD2, a ganglioside found in neuroectoderm-derived tumors and sarcomas. The product was developed by Memorial Sloan Kettering Cancer Center and is exclusively licensed to Y-mAbs.
In November 2024, Nobelpharma Co., Ltd., a pharmaceutical company based in Japan that focuses on developing curative drugs and medical devices, formed a partnership with Y-mAbs Therapeutics Inc. Under the agreement, Nobelpharma will take responsibility for the development, regulatory submission, and marketing of Danyelza in Japan, including sales and distribution, if the product is approved. Y-mAbs Therapeutics Inc. specializes in cancer immunotherapies, including Danyelza.
The key player in the danyelza market is Y-mAbs Therapeutics Inc.
North America was the largest region in the danyelza market in 2024. The regions covered in danyelza report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the danyelza market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Danyelza, also known as naxitamab, is a monoclonal antibody combined with granulocyte-macrophage colony-stimulating factor (GM-CSF) to treat specific high-risk cancers. It is primarily approved for pediatric patients aged 1 year and older, as well as adults with relapsed or refractory high-risk neuroblastoma that affects the bone or bone marrow, especially in cases where previous treatments resulted in only partial or stable responses. Danyelza targets GD2, a molecule commonly found on neuroblastoma cells, allowing the immune system to effectively attack these cancer cells.
The main indications for Danyelza include neuroblastoma, osteosarcoma, and other GD2-positive cancers. Neuroblastoma, a cancer that forms in nerve cells and primarily affects children, is one of the key conditions treated with Danyelza. The drug is gaining traction as more therapies for pediatric cancers are approved. Treatment types for Danyelza include monotherapy, combination therapy, with end users typically found in hospitals, specialty clinics, and cancer or radiation therapy centers.
The danyelza market research report is one of a series of new reports that provides danyelza market statistics, including danyelza industry global market size, regional shares, competitors with a danyelza market share, detailed danyelza market segments, market trends and opportunities, and any further data you may need to thrive in the danyelza industry. This danyelza market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The danyelza market consists of sales of genetically modified donor pancreas cells, cell transplantation, and immune suppression drugs. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Market growth during the historic period can be attributed to the increasing incidence of neuroblastoma, FDA approvals and regulatory support, broader clinical applications, higher research investments in immunotherapy, and growing healthcare expenditures.
Growth during the market's forecast period can be attributed to the increasing incidence of cancer, heightened awareness of targeted therapies, improved patient outcomes, growing demand for pediatric cancer treatments, and advancements in diagnostic tools. Key trends expected in the forecast period include progress in drug formulation, innovations in targeted therapy, greater outsourcing of clinical trials, integration of digital health solutions in clinical trials, and a stronger focus on pediatric research and innovation.
The rising prevalence of pediatric cancers is expected to drive the growth of the Danyelza market. Pediatric cancers include various types such as leukemia, brain tumors, neuroblastoma, and lymphomas that affect children and adolescents. This increase in pediatric cancer cases is linked to factors such as advancements in diagnostic techniques, environmental exposures, genetic factors, and the long-term effects of cancer treatments. Danyelza (naxitamab) is a targeted immunotherapy that plays a significant role in treating high-risk neuroblastoma, a type of cancer that can be difficult to manage. When used alongside other treatments, Danyelza has shown improvements in survival rates and has helped slow disease progression in children with this aggressive cancer. For example, in October 2024, the Cancer Council, an Australian non-profit organization, reported that in 2022, approximately 93 children aged 0-14 years died from cancer in Australia. In addition, there were 206 new cancer diagnoses in children under 15 and 263 in adolescents aged 15-24 in Victoria. By 2023, there were 6,197 males and 5,523 females alive who had been diagnosed with cancer during childhood or adolescence. The growing prevalence of pediatric cancers is thus driving the demand for Danyelza.
A significant trend in the Danyelza market is the development of targeted immunotherapy treatments that aim to improve options for treating neuroblastoma and other cancers. Targeted immunotherapy uses substances to directly target cancer cells, focusing on specific proteins or markers, such as GD2 in neuroblastoma, to help the immune system destroy the cancer cells. For example, in May 2023, Y-mAbs Therapeutics Inc., a US-based biotechnology company, received marketing authorization from Brazil's Agência Nacional de Vigilância Sanitaria for Danyelza (naxitamab-gqgk) 40 mg/10 mL injection, which is used to treat high-risk neuroblastoma. Danyelza is a recombinant humanized monoclonal antibody designed to target GD2, a ganglioside found in neuroectoderm-derived tumors and sarcomas. The product was developed by Memorial Sloan Kettering Cancer Center and is exclusively licensed to Y-mAbs.
In November 2024, Nobelpharma Co., Ltd., a pharmaceutical company based in Japan that focuses on developing curative drugs and medical devices, formed a partnership with Y-mAbs Therapeutics Inc. Under the agreement, Nobelpharma will take responsibility for the development, regulatory submission, and marketing of Danyelza in Japan, including sales and distribution, if the product is approved. Y-mAbs Therapeutics Inc. specializes in cancer immunotherapies, including Danyelza.
The key player in the danyelza market is Y-mAbs Therapeutics Inc.
North America was the largest region in the danyelza market in 2024. The regions covered in danyelza report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the danyelza market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Danyelza, also known as naxitamab, is a monoclonal antibody combined with granulocyte-macrophage colony-stimulating factor (GM-CSF) to treat specific high-risk cancers. It is primarily approved for pediatric patients aged 1 year and older, as well as adults with relapsed or refractory high-risk neuroblastoma that affects the bone or bone marrow, especially in cases where previous treatments resulted in only partial or stable responses. Danyelza targets GD2, a molecule commonly found on neuroblastoma cells, allowing the immune system to effectively attack these cancer cells.
The main indications for Danyelza include neuroblastoma, osteosarcoma, and other GD2-positive cancers. Neuroblastoma, a cancer that forms in nerve cells and primarily affects children, is one of the key conditions treated with Danyelza. The drug is gaining traction as more therapies for pediatric cancers are approved. Treatment types for Danyelza include monotherapy, combination therapy, with end users typically found in hospitals, specialty clinics, and cancer or radiation therapy centers.
The danyelza market research report is one of a series of new reports that provides danyelza market statistics, including danyelza industry global market size, regional shares, competitors with a danyelza market share, detailed danyelza market segments, market trends and opportunities, and any further data you may need to thrive in the danyelza industry. This danyelza market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The danyelza market consists of sales of genetically modified donor pancreas cells, cell transplantation, and immune suppression drugs. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Danyelza Market Characteristics4. Danyelza Market Trends and Strategies5. Danyelza Market -Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market7. Global Danyelza Pricing Analysis & Forecasts30. Global Danyelza Market Competitive Benchmarking and Dashboard31. Key Mergers and Acquisitions in the Danyelza Market32. Recent Developments in the Danyelza Market
3. Danyelza Market Biologic Drug Characteristics
6. Global Danyelza Growth Analysis and Strategic Analysis Framework
8. Danyelza Market Segmentation
9. Global Danyelza Epidemiology of Clinical Indications
10. Danyelza Market Regional and Country Analysis
11. Asia-Pacific Danyelza Market
12. China Danyelza Market
13. India Danyelza Market
14. Japan Danyelza Market
15. Australia Danyelza Market
16. South Korea Danyelza Market
17. Western Europe Danyelza Market
18. UK Danyelza Market
19. Germany Danyelza Market
20. France Danyelza Market
21. Eastern Europe Danyelza Market
22. North America Danyelza Market
23. USA Danyelza Market
24. Canada Danyelza Market
25. South America Danyelza Market
26. Middle East Danyelza Market
27. Africa Danyelza Market
28. Danyelza Market Competitive Landscape and Company Profiles
29. Global Danyelza Market Pipeline Analysis
33. Danyelza Market High Potential Countries, Segments and Strategies
34. Appendix
Executive Summary
Danyelza Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on danyelza market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for danyelza? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The danyelza market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) by Indication: Neuroblastoma; Osteosarcoma and Other GD2-Positive Cancers2) by Treatment Type: Monotherapy; Combination Therapy
3) by End User: Hospitals; Specialty Clinics; Cancer and Radiation Therapy Center
Key Companies Mentioned:Y-mAbs Therapeutics Inc.
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Y-mAbs Therapeutics Inc.
